URGN Logo

UroGen Pharma Ltd. (URGN) 

NASDAQ
Market Cap
$510M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
751 of 776
Rank in Industry
416 of 433

Largest Insider Buys in Sector

URGN Stock Price History Chart

URGN Stock Performance

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma …

Insider Activity of UroGen Pharma Ltd.

Over the last 12 months, insiders at UroGen Pharma Ltd. have bought $0 and sold $543,940 worth of UroGen Pharma Ltd. stock.

On average, over the past 5 years, insiders at UroGen Pharma Ltd. have bought $520,273 and sold $354,589 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 160 shares for transaction amount of $2,096 was made by Schoenberg Mark (Chief Medical Officer) on 2021‑11‑18.

List of Insider Buy and Sell Transactions, UroGen Pharma Ltd.

2024-09-09SaleChief Medical Officer
859
0.002%
$13.08$11,236-4.87%
2024-09-09SaleGeneral Counsel
1,521
0.0035%
$13.08$19,895-4.87%
2024-06-10SaleChief Medical Officer
5,153
0.0146%
$13.08$67,401+8.46%
2024-03-18SaleChief Medical Officer
12,000
0.0341%
$14.05$168,600-5.31%
2024-02-01SaleChief Medical Officer
3,789
0.0123%
$15.78$59,790-10.66%
2024-02-01SaleGeneral Counsel
4,993
0.0162%
$15.78$78,790-10.66%
2024-01-31SaleChief Medical Officer
3,789
0.0122%
$15.74$59,639-9.49%
2024-01-31SaleGeneral Counsel
4,993
0.0161%
$15.74$78,590-9.49%
2023-08-31SaleGeneral Counsel
3,800
0.0129%
$18.01$68,438-17.28%
2023-01-31SaleChief Medical Officer
1,900
0.0079%
$10.12$19,228+14.63%
2023-01-31SaleGeneral Counsel
1,636
0.0068%
$10.12$16,556+14.63%
2022-10-31SaleChief Medical Officer
258
0.0011%
$11.85$3,057-12.49%
2022-08-31SaleGeneral Counsel
3,606
0.0153%
$7.21$25,999+29.46%
2022-07-31SaleChief Medical Officer
259
0.0011%
$7.81$2,023
2022-04-30SaleChief Medical Officer
254
0.001%
$6.62$1,681
2022-01-31SaleChief Executive Officer
8,195
0.0356%
$7.58$62,118+5.96%
2022-01-31SaleChief Medical Officer
1,374
0.006%
$7.58$10,415+5.96%
2022-01-31SaleGeneral Counsel
414
0.0018%
$7.58$3,138+5.96%
2022-01-31SaleChief Financial Officer
331
0.0014%
$7.58$2,509+5.96%
2022-01-26SaleChief Medical Officer
111
0.0005%
$8.09$898+4.48%

Insider Historical Profitability

<0.0001%
Schoenberg MarkChief Medical Officer
145091
0.3445%
$12.11328<0.0001%
Smith Jason DrewGeneral Counsel
25226
0.0599%
$12.1118<0.0001%
Barrett Elizabeth A.Chief Executive Officer
300985
0.7147%
$12.1142<0.0001%
Henderson MollyChief Financial Officer
5248
0.0125%
$12.1112<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RTW Investments, LP$48.86M7.913.26M+88.63%+$22.96M0.73
RA Capital Management, L.P.$46.25M7.493.08M0%+$00.05
Great Point Partners$39.31M6.372.62M0%+$06.59
Menora Mivtachim Holdings Ltd$34.55M5.592.3M0%+$00.27
BlackRock$25.75M4.171.72M-0.14%-$37,365.00<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.